COVID-19 and its implications for thrombosis and anticoagulation


26 May 2020

The puzzling pathogenesis behind COVID-19 has thrown up many clinical dilemmas for physicians across the globe, including cardiologists.

The rapid accumulation of evidence indicates the presence of a hypercoagulable state in patients with severe COVID-19 which in turn increases the risk of thromboembolic complications.

Join us and a leading panel of experts, including Professor Beverley Hunt OBE, a consultant in thrombosis and haemostasis at King’s College London, to explore the diagnostic and therapeutic approaches to managing these patients.

There will be an opportunity to ask the panel questions. The webinar will be available on demand after the event.

Thursday 28th May | 7pm to 8pm AEST


Hosted by:

Professor Jenny Curnow

Director of Clinical Haematology, WSLHD, Westmead hospital. She is chair of the NSW Clinical Excellence Commission Anticoagulant medicines working party and the THANZ Education committee.

With special guests:

Professor Beverley Hunt OBE

Professor of Thrombosis & Haemostasis, King’s College London. Consultant, Guy’s and St Thomas’ NHS Foundation Trust. Clinical Lead in Haematological Sciences at Viapath. Medical Director, Thrombosis UK.

Associate Professor Huyen Tran

Staff haematologist, The Alfred Hospital & Monash Medical Centre. Head, Thrombosis & Haemostasis Unit. Director, Haemophilia Centre. Member of National COVID-19 Clinical Evidence Taskforce.

Doctor Emmanuel J Favaloro

Editor in Chief, Seminars in Thrombosis and Hemostasis, Adjunct Professor, Charles Sturt University.

This webinar was developed independently by the limbic. Thank you to Sanofi-aventis Australia Pty Ltd for providing the financial support that made it possible.


Already a member?

Login to keep reading.

Email me a login link